A Phase Ib/II, Multi-center, Study of Oral LGH447 in Combination With Oral BYL719 in Patients With Relapsed and Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2018
Price : $35 *
At a glance
- Drugs Alpelisib (Primary) ; PIM 447 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 26 Jan 2016 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 04 Aug 2015 Planned End Date changed from 1 Nov 2016 to 1 Dec 2015 as per ClinicalTrials.gov record.